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Abstract
Background:  Fibroblast growth factor 20 (FGF20) is a neurotrophic factor preferentially
expressed in the substantia nigra of rat brain and could be involved in dopaminergic neurons
survival. Recently, a strong genetic association has been found between FGF20 gene and the risk of
suffering from Parkinson's disease (PD). Our aim was to replicate this association in two
independent populations.
Methods: Allelic, genotypic, and haplotype frequencies of four biallelic polymorphisms were
assessed in 151 sporadic PD cases and 186 controls from Greece, and 144 sporadic PD patients
and 135 controls from Finland.
Results: No association was found in any of the populations studied.
Conclusion: Taken together, these findings suggest that common genetic variants in FGF20 are
not a risk factor for PD in, at least, some European populations.
Background
Parkinson's disease (PD), with a prevalence of nearly 2%
in those older than 65 years of age, is one of the most
common neurodegenerative disorders [1]. The cause of its
clinical features (bradykinesia, rigidity, resting tremor,
and postural instability) is the selective degeneration of
dopaminergic neurons in the substantia nigra, leading to
a deficiency of dopamine in their striatal projections
areas. Although the etiology of PD is still unclear, increas-
ing evidence suggest that genetic factors are likely to con-
tribute [2,3]. To date, mutations in seven genes have been
related to mendelian forms of the disease, and several loci
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across the genome have also been identified to be influ-
encing not only familial, but also sporadic forms of PD [4-
6]. One of the extant linkages to late onset PD is on chro-
mosome 8p [7]. Analysis of candidate genes located
within the region through the use of the pedigree disequi-
librium test in 644 families, demonstrated a significant
association between several polymorphisms at the fibrob-
last growth factor 20 (FGF20) and PD [8]. FGF20 is a neu-
rotrophic factor widely expressed in dopaminergic
neurons of the substantia nigra pars compacta [9], and
enhances the survival of midbrain dopaminergic neurons
[10].
We have attempted to replicate the previously described
association by performing a case-control analysis in two
different series: one from Finland and the other from
Greece.
Methods
Patients and healthy individuals
The Finnish series is composed of 144 sporadic PD
patients (mean age 67.2 years, range 38 to 88, 41%
women) and 135 neurologically normal healthy control
subjects (mean age 65.8 years, range 37 to 80, 64%
women). Eleven patients had an onset before 45 years old.
All individuals were recruited from the Neurological out-
patient clinics of the Helsinki University Central Hospital
and Seinäjoki Central Hospital. Patients were diagnosed
according to PD Society Brain Bank criteria [11] and were
either followed for at least 4 years or, alternatively, clinical
follow-up for at least 2 years plus 123I-β -CIT-SPECT find-
ings supporting idiopathic PD. Patients with dementia or
patients who reported first-degree relatives with parkin-
sonism were excluded. Written informed consent was
obtained from all participants. The Ethical Review Com-
mittee of the Department of Neurology at the Helsinki
University Central Hospital approved the study.
The Greek series is composed of 151 sporadic PD patients
(mean age 70.3, range 40 to 95, 46% women) and 186
age-, gender-and ethnicity-matched neurologically
healthy controls. Three patients had an onset before 45
years old. All patients were residents of Thessaly (Central
Greece) and were identified prospectively during a 3-year
period (2001–2004) in the outpatient clinic for move-
ment disorders in Larissa University Hospital and were
followed up for at least one year and up to 3 years. The
diagnosis of PD was based on established criteria [4].
After approval from Hospital Scientific Committee and
informed consent, blood samples were drawn for DNA
extraction from patients and controls.
Genotyping
Taqman® Assays-by-DesignSM SNP Genotyping (Applied
Biosystems) based assays were employed for allelic dis-
crimination of the two intronic SNPs (rs1989756 and
rs1989754) as well as the 3'UTR SNP rs1721100. Thermal
cycling and end-point PCR analysis was performed on an
ABI PRISM® 7900HT Sequence Detection System and ana-
lyzed with SDS software (Applied Biosystems). Another
SNP at the 3'UTR (rs20399075), which is located 99 base
pairs (bp) from rs1721100, was genotyped using a restric-
tion fragment length polymorphism (RFLP) approach. In
brief, a PCR was conducted using the following primers:
forward, 5'-AGTCTATTTTCTACTGAGAG-3'; and reverse,
5'-TAAGGACTAATCCAATGTATC-3'. The 139 bp ampli-
fied product was digested with 10 units of BspHI restric-
tion enzyme and fragments were resolved on a 2% agarose
gel stained with ethidium bromide. Two fragments of 80
bp and 59 bp appeared when a PCR fragment containing
a cytosine in the polymorphic site was present.
Statistical analysis
Odds ratios and Chi square tests were calculated using
SPSS v11.0 software for windows. Linkage disequilibrium
was assessed by means of a genotype association test,
implemented in the Arlqeuin ver.2.000 program, and
haplotype frequencies were estimated with an expecta-
tion-maximization (EM) algorithm, also implemented in
the Arlequin ver.2.000 program [12]. Comparison of
FGF20 haplotype frequencies between cases and controls
was performed using Fisher's exact test. Power calcula-
tions were performed with the epidemiological program
EpiInfo version 6. Pomelo Tool software http://
pomelo.bioinfo.cnio.es was used for multiple testing
corrections.
Results
Distribution of genotype frequencies are presented in
Table 1. All polymorphisms were in Hardy-Weinberg
equilibrium for PD patients and controls in both the
Greek and the Finnish series. No statistically significant
differences in genotype frequency were found between
cases and controls in the Greek series. Allele frequencies
also showed no significant association with disease in this
series (data not shown). When we focused on the Finnish
individuals, a slightly but not significant overrepresenta-
tion of the GG genotype in the two intronic polymor-
phisms (rs1989756 and rs1989754) was identified in
patients compared to controls (P  = 0.087 and 0.089
respectively). There was significant increase in the
rs1989754 G allele in patients compared to control Finn-
ish individuals (52% vs. 42%, P = 0.030). Comparison of
the rs1989756, rs1721100, and ss20399075 allele fre-
quencies did not reveal any significant differences (P =
0.099, P = 0.239, and P = 0.424 respectively). RepeatingBMC Neurology 2005, 5:11 http://www.biomedcentral.com/1471-2377/5/11
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the analyses after the exclusion of all early onset cases did
not result in any significant changes (data not shown).
Linkage disequilibrium (LD) analysis revealed a strong LD
between all the neighboring markers (P values < 0.01 in
all comparisons). Only the neighboring SNPs rs1721100
and ss20399075 did not show significant LD in the Finn-
ish control group.
No significant difference in the distribution of four
marker haplotypes between cases and controls was found
in either of the series (see Table 2). Just a slightly decrease
of the GGCC haplotype in Greek PD patients was found
compared to control individuals (P = 0.073).
Table 1: FGF20 genotype frequencies in cases and controls
Finnish series Greek series
rs1989756 PD cases (%) Controls (%) PD cases (%) Controls (%)
GG 130 (90.3) 110 (83.3) 124 (82.1) 153 (83.6)
GA 14 (9.7) 22 (16.7) 25 (16.6) 29 (15.8)
AA 0 0 2 (1.3) 1 (0.5)
χ 2 (2 df); 2.928 P = 0.087 χ 2 (2 df); 0.605 P = 0.739
rs1989754
GG 39 (27.1) 27 (20.1) 30 (20.0) 34 (19.2)
GC 71 (49.3) 60 (44.8) 63 (42.0) 85 (48.0)
CC 34 (23.6) 47 (35.1) 57 (38.0) 58 (32.8)
χ 2 (2 df); 4.838 P = 0.089 χ 2 (2 df); 1.309 P = 0.520
rs1721100
CC 74 (51.4) 68 (51.9) 73 (50.3) 90 (50.3)
CG 60 (41.7) 48 (36.6) 57 (39.3) 75 (41.9)
GG 10 (6.9) 15 (11.5) 15 (10.3) 14 (7.8)
χ 2 (2 df); 1.977 P = 0.372 χ 2 (2 df); 0.702 P = 0.704
ss20399075
TT 8 (6.6) 4 (3.3) 2 (1.4) 0
TC 36 (29.5) 36 (29.5) 32 (21.8) 39 (21.7)
CC 78 (63.9) 82 (67.2) 113 (76.9) 141 (78.3)
χ 2 (2 df); 1.433 P = 0.488 χ 2 (2 df); 2.472 P = 0.291
Table 2: FGF20 haplotype frequencies distributions
Finnish sample a Greek sample b
PD cases Controls PD cases Controls
G G C C 42.6% 33.8% 33.8% 40.4%
G C G C 17.9% 23.4% 17.0% 19.4%
G C C C 16.1% 15.7% 21.4% 19.4%
G G C T 8.6% 8.2% 2.6% 1.9%
G C G T 8.2% 5.6% 9.2% 8.0%
A C C C 2.4% 8.3% 9.6% 8.2%
* 4.8% 5.0% 6.4% 2.7%
a Fisher's exact test, P = 0.113.
b Fisher's exact test, P = 0.073
* Other haplotypes with frequencies lower than 5%.
The order of SNPs are: rs1989756, rs1989754, rs1721100, and ss20399075.BMC Neurology 2005, 5:11 http://www.biomedcentral.com/1471-2377/5/11
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Discussion
Among all the comparisons that we have performed; only
polymorphism rs1989754 G allele frequency was signifi-
cantly higher in patients than controls in the Finnish
sample. However, when we adjusted for multiple testing
in order to control for a type I error by means of a permu-
tation test, the P value was not longer significant.
Taking into account the allele frequencies, our study has a
power of detecting risks from 1.7 to 3.6 in the Finnish
sample and from 1.6 to 2.1 in the Greek series with 80%
power (95% confidence interval). These results, thus, sug-
gest that FGF20 is not a major risk factor for sporadic PD
in the Finnish and Greek population.
The present work does not replicate the recently reported
association between polymorphisms at the FGF20 gene
and PD [8]. It is important to note that we have genotyped
the same polymorphisms that they previously performed
except the one located upstream the exon 1 (ss20399076)
because this was not found in the SNP database and we
could not localize this SNP based on the published report.
Nevertheless, because no association was reported
between this SNP and PD, the absence of this polymor-
phism in our work should not be a major limitation.
Several reasons could explain the discrepancy between
our results and the one by Van der Walt and collaborators
[8]: first, the reported positive association could be the
result of a type I error, due to possible admixture. Popula-
tion stratification due to ethnic admixture could have
been the result of using US based sample, which was not
fully detailed by the authors. Another possible explana-
tion for the lack of replication could be the result of using
different epidemiological approaches. We believe that the
association reported by Walt et al. should be strong
enough to be consistent when other genetic epidemiology
methods are employed. Since the reported p values are in
the order of 1*10E-3, one could expect a similar pattern of
association, independently of the method utilized. There-
fore, it seems very improbable that the lack of replication
is due to the use of another methodology. A third interpre-
tation could be that the association is real but the effect is
smaller in Greek and Finnish individuals. If this was true,
our series may not be large enough to assess variants that
contribute to complex traits and are likely to have modest
effects. Fourth and finally, a real association could exist
only in groups of a specific ethnic origin and, presumably,
a similar genetic background.
Conclusion
In order to test whether the previously described associa-
tion between FGF20 and PD is consistent in other popu-
lations, we have performed a case-control study in which
we compare and analyze four biallelic polymorphisms
within  FGF20  gene in two different populations from
Europe: one from Greece and one from Finland. Our
results clearly indicate that genetic variations in FGF20 do
not influence the risk of PD in these two populations. As
far as we know, this is the only study that has tried to rep-
licate the previous reported association between FGF20
and PD.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
JC performed the genotyping, statistical analysis, and
drafted the manuscript. GX, JE, VG, OH, ED, TP, AP,
GMH, and PJT, contributed to collecting materials and
participated in its design and coordination together with
drafting the manuscript. ABS conceived the study and par-
ticipated in the conceptual design and coordination of
this work, together with drafting the manuscript.
Acknowledgements
Supported in part by the Helsinki University Central Hospital, The Finnish 
Cultural Foundation.
References
1. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L,
Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA:
Prevalence of parkinsonism and Parkinson's disease in
Europe: the EUROPARKINSON Collaborative Study. Euro-
pean Community Concerted Action on the Epidemiology of
Parkinson's disease.  J Neurol Neurosurg Psychiatry 1997, 62:10-15.
2. Sveinbjornsdottir S, Hicks AA, Jonsson T, Petursson H, Gugmundsson
G, Frigge ML, Kong A, Gulcher JR, Stefansson K: Familial aggrega-
tion of Parkinson's disease in Iceland.  N Engl J Med 2000,
343:1765-1770.
3. Payami H, Zareparsi S, James D, Nutt J: Familial aggregation of
Parkinson disease: a comparative study of early-onset and
late-onset disease.  Arch Neurol 2002, 59:848-850.
4. Hardy J, Cookson MR, Singleton A: Genes and parkinsonism.  Lan-
cet Neurol 2003, 2:221-228.
5. Gwinn-Hardy K: Genetics of parkinsonism.  Mov Disord 2002,
17:645-656.
6. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M,
de Munain AL, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR,
Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF,
Perez-Tur J, Wood NW, Singleton AB: Cloning of the gene con-
taining mutations that cause PARK8-linked Parkinson's
disease.  Neuron 2004, 44:595-600.
7. Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K,
Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen
FHJ, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Sta-
jich JM, Slotterbeck B, Booze MW, Ribble RC, Rampersaud E, West
SG, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Vance
JM, Pericak-Vance MA: Complete genomic screen in Parkinson
disease: evidence for multiple genes.  Jama 2001,
286:2239-2244.
8. van der Walt JM, Noureddine MA, Kittappa R, Hauser MA, Scott WK,
McKay R, Zhang F, Stajich JM, Fujiwara K, Scott BL, Pericak-Vance
MA, Vance JM, Martin ER: Fibroblast growth factor 20 polymor-
phisms and haplotypes strongly influence risk of Parkinson
disease.  Am J Hum Genet 2004, 74:1121-1127.
9. Ohmachi S, Watanabe Y, Mikami T, Kusu N, Ibi T, Akaike A, Itoh N:
FGF-20, a novel neurotrophic factor, preferentially
expressed in the substantia nigra pars compacta of rat brain.
Biochem Biophys Res Commun 2000, 277:355-360.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neurology 2005, 5:11 http://www.biomedcentral.com/1471-2377/5/11
Page 5 of 5
(page number not for citation purposes)
10. Ohmachi S, Mikami T, Konishi M, Miyake A, Itoh N: Preferential
neurotrophic activity of fibroblast growth factor-20 for
dopaminergic neurons through fibroblast growth factor
receptor-1c.  J Neurosci Res 2003, 72:436-443.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diag-
nosis of idiopathic Parkinson's disease: a clinico-pathological
study of 100 cases.  J Neurol Neurosurg Psychiatry 1992, 55:181-184.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/5/11/prepub